NCT03366675View on ClinicalTrials.gov

AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]

PHASE2TerminatedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

October 8, 2018

Study Completion Date

October 29, 2018

Conditions

Small Cell Lung Cancer

Interventions

DRUG

AZD2811

AZD2811 100mg/vial

Trial Locations (1)

Unknown

Samsung Medical center, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Samsung Medical Center

OTHER